Open Access

DNA methylation in the human placenta and fetal growth (Review)

  • Authors:
    • Ourania Koukoura
    • Stavros Sifakis
    • Demetrios A. Spandidos
  • Corresponding author:
  • View Affiliations

  • Published online on: Tuesday, January 24, 2012
  • Pages: 883-889 DOI: 10.3892/mmr.2012.763
  • Copyright: © Koukoura et al. This is an open access article distributed under the terms of a Creative Commons Attribution License.

Abstract

Throughout in utero development, the placenta plays a key role in controlling growth and development. The placenta acts not only as a gatekeeper of nutrient and waste exchange between mother and developing fetus, but also as a regulator of the intrauterine environment. Its functions can be influenced by the environment encountered throughout pregnancy, thereby altering the appropriate genetic programming needed to allow for appropriate fetal growth. Epigenetic alterations related to environmental exposures have been linked to aberrant fetal growth. DNA methylation, which is the best known DNA epigenetic modification, may provide an attractive mechanism linking environmental cues to placental pathology, with consequences for fetal growth and adult life. Alteration of the methylation patterns of genes expressed in the placenta has recently been found to modify gene expression and subsequently impair function of the placenta. Although there is strong evidence to demonstrate that the environment can affect the pattern of DNA methylation of the placenta during fetal development, a direct association between environmental conditions, methylation alterations and gene expression is difficult to confirm. DNA methylation in the placenta has mainly been investigated in the context of imprinted and non-imprinted genes transcription. Several environmental factors have also been assessed in regard to their association with changes to the epigenetic motives of embryonic and extraembryonic tissues and their impact on pregnancy outcome. In this review, we briefly present the available evidence regarding the role of DNA methylation patterns of the placenta on aberrant fetal growth.

1. Introduction

Epigenetics constitutes an important mechanism capable of regulating gene transcription, linking early life’s events to adult morbidity. It entails heritable changes in chromatin that alter gene expression without altering the DNA sequence (1,2). It is the best-characterized epigenetic modification. Evidence suggests that DNA methylation is closely involved in the regulation of gene expression and that DNA methylation patterns can be distorted during the pathogenetic process of a disease (3). Findings of previous reports suggest that DNA methylation is altered during development and by environmental stress (4,5). However, the mechanisms by which these epigenetic effects are exerted remain to be clarified. In this review, we briefly present the available evidence regarding the role of DNA methylation patterns of the placenta on aberrant fetal growth.

2. DNA methylation

DNA methylation, which is accomplished by DNA- methyltransferases, occurs on the cytosine residues of CG (also designated CpG) dinucleotides. Enzymes known as DNA methyltransferases (DNMTs) catalyse the addition of a methyl group to the cytosine ring to form methyl cytosine, using S-adenosylmethionine as a methyl donor (6). DNA methyltransferase-1 (DNMT1) is the predominant mammalian DNA methylating enzyme responsible for the restoration of hemi-methylated sites to full methylation, termed maintenance methylation, which occurs after DNA replication. DNMT3A and DNMT3B are mainly involved in the methylation of new sites, known as de novo methylation (7). DNMT3L is postulated to play a regulatory role in DNA methylation without DNA methyltransferase activity in itself. In humans and other mammals, DNA modification occurs predominantly on cytosines that precede a guanosine in the DNA sequence (6). These dinucleotides can be clustered in small stretches of DNA, termed CpG islands, which are often associated with promoter regions. In 98% of the genome, CpGs are present approximately once per 80 dinucleotides. By contrast, CpG islands, which comprise 1–2% of the genome, are approximately 200 base pairs (bp) to several kb in length and have a frequency of CpGs approximately five times greater than the genome as a whole (8,9). Most CpG sites outside the CpG islands are methylated, suggesting a role in the global maintenance of the genome, while most CpG islands in gene promoters are unmethylated, which allows active gene transcription (6,10). When a CpG becomes methylated in a cell, it remains methylated in all its descendants (11). Generally, when a given stretch of cytosines in a CpG island located in the promoter region of a gene is methylated, that gene is silenced by methylation; such a CpG island would be termed ‘hypermethylated’. Conversely, when a given stretch of cytosines in a CpG island located in the promoter region of a gene is not methylated, that gene is not silenced by methylation; the CpG island in this case would be ‘hypomethylated’ (12). Methylation of promoters inhibits their recognition by transcription factors and RNA polymerase, as methylated cytosines preferentially bind to a protein known as methyl cytosine binding protein, or MeCP. When a promoter region normally recognized by an activating transcription factor, is methylated, its transcription is inhibited (9).

3. DNA methylation in the developing embryo and placenta

Methylation of gene promoters is probably one of the foremost mechanisms responsible for cell differentiation during embryogenesis: the transcription of unwanted genes is eliminated by methylation of their promoters (13). As oocytes and spermatozoa are more differentiated than the pluripotent cells of the early embryo, the DNA of morula (16-cell embryo, third day post-conception) undergoes global demethylation. CpGs are demethylated on a large scale, thus reactivating the near-totality of the genome (a few genes escape this demethylation, e.g., the genes subject to genomic imprinting). Subsequently, as cells start differentiating, the gene promoters involved in this differentiation become methylated according to a strict sequence depending on each cell type (14).

On fertilisation a rapid paternal-specific asymmetric loss of methylation is observed (15,16). This process occurs in the absence of transcription or DNA replication and is termed active demethylation. Thereafter, there is a step-wise decline in methylation until the morula stage (17,18). The initiation of the de novo methylation occurs after the fifth cell cycle and coincides with the time of the first differentiative event. The establishment of the first two cell lineages results in a significant asymmetry. The inner cell mass (ICM), which gives rise to all the tissues of the adult, becomes hypermethylated, while the trophectoderm (TE), which forms most of the structure of the placenta, is hypomethylated (17,18). This differential methylation is maintained and reflected in highly methylated somatic tissues and the distinctively hypomethylated extra-embryonic tissues of the placenta. This epigenetic inequality with higher overall DNA methylation levels in the embryo compared with the placenta is maintained throughout gestation (18).

4. Imprinting

Despite the genome-wide decline in DNA methylation, certain sequences remain refractory to the general demethylation during preimplantation development. Imprinted genes escape this epigenetic reprogramming (15). They are protected from demethylation because it is crucial that the parental imprints are preserved in the developing embryo (19).

Genomic imprinting refers to silencing of one parental allele in the zygotes of gametes leading to monoallelic expression of these genes in the offspring. During the process of imprinting, the male and female germ line confer a gender-specific mark (imprint) on certain chromosomal regions (20). Only one allele of the imprinted genes, the maternal or paternal, can be active and expressed. Each cluster is controlled by an imprinting control region (ICR) that usually contains a stably maintained or developmentally changing Differentially Methylated Region (DMR) (21,22). Genomic imprinting arose during the mammalian evolution (approximately 150 million years ago) and may be associated with the evolution of intrauterine development that requires the formation of a placenta (20).

The prevailing hypothesis on the evolution of genomic imprinting is the ‘conflict hypothesis’ theory. This theory suggests that paternally expressed genes strongly favor using maternal resources to benefit offspring, while maternally expressed genes attempt to preserve such maternal resources and thus, are in direct conflict with one another. Many imprinted genes are involved in fetal development and growth, and some affect behaviour (20,23). Imprinting appears to be particularly important for placental development (24,25). Knockout studies of several paternally or maternally imprinted genes result in intrauterine growth restriction (IUGR) and smaller placental size or the overgrowth and hyperplasia of the placenta, respectively (2527). Certain maternal genes are required for proper development of the embryo, whereas extraembryonic tissues depend on the presence of active paternal genes. Approximately 60 genes have been shown to be imprinted in humans, two thirds of which are paternally expressed (maternally imprinted) and one third maternally expressed (paternally imprinted) (28).

5. DNA methylation in the placenta

Throughout in utero development, the placenta plays an important role in controlling growth and development through the transfer of nutrients and waste, and in protecting the fetus from insults (29). Findings of recent studies have shown that placental genetic and epigenetic profiles may serve as markers of the intrauterine and extrauterine environment (3032). Embryonic and fetal growth depends on genetic, epigenetic and environmental factors, and the process is the result of the interaction between these factors. Approximately 7–9% of live-born infants have a birth weight below the 10th percentile. Intrauterine growth restriction describes a decrease in the fetal growth rate that prevents an infant from obtaining his or her complete growth potential (33). IUGR infants are small for gestational age (SGA) if their birth weight measures <10 to 3% using standard growth curves (34,35). Therefore, the terms IUGR and SGA are related but not synonymous. The IUGR is a pathological condition, whereas SGA may reflect a normal pattern in a given population. The placenta forms the interface between the fetal and maternal circulations. For this reason, fetal disease, maternal disease, primary placental disease, and extrinsic factors could all interfere with the efficiency of nutrient and waste exchange and result in growth restriction (36,37). Fetal growth restriction is a physical sign rather than a single disease. Improper placental function accounts for the majority of IUGR cases.

Epigenetic modification in the placenta may provide an attractive mechanism linking environmental cues to placental pathology, with consequences for fetal growth and adult life. Accumulating evidence suggests that the maternal nutritional status is capable of altering the epigenetic state of the fetal genome and imprinted gene expression. Epigenetic alterations in early embryos may be carried forward to subsequent developmental stages (38). The placenta has been reported to present high variability in overall DNA methylation compared to other tissues (39), probably in response to its role in mediating the conflicting demands of mother and fetus (40). Methylation patterns of several genes (imprinted and non-imprinted) in the placenta have been investigated in an attempt to elucidate the exact role of epigenetic modifications on fetal growth. Administration of a DNA methyltransferase inhibitor to pregnant rats at different gestational ages resulted in significantly smaller placentas and histological evaluation showed the labyrinthine part of the placenta to be severely reduced (41). In a similar study, a lack of the labyrinth layer was observed with a strong proliferative activity of the cells in the basal layer or complete disruption of the placental structure (42). Furthermore, administration of the same agent in human choriocarcinoma-derived cell lines, resulted in disrupted trophoblast migration (43).

DNA methylation and gene transcription

Much of the recent research on placental epigenetics has focused on imprinted genes that are known to affect growth, such as insulin-like growth factor 2 (IGF2). IGF2 and H19 are two oppositely expressed imprinted genes located adjacent to each other at 11p15.5 that share the same transcription regulatory epigenetic mechanisms and have an important role in feto-placental development. The DMR upstream of H19, which harbors sequences known to bind to the zinc finger protein CTCF, if methylated on the paternal chromosome prevents binding with CTCF and allows the IGF2 promoter to assess enhancers located downstream of H19, thereby expressing IGF2 (Fig. 1). On the maternal chromosome the non-methylated H19 DMR is bound to CTCF, thus insulating the IGF2 promoter from the 3′ enhancers and allowing the H19 promoter unimpeded access to the enhancers. Maternal H19 is subsequently transcribed (44). IGF2 is highly expressed in normal mouse and human placenta and affects the functional capacity of the placenta to transfer nutrients to the fetus as well as placental size (45,46). It is expressed in most tissues only from the paternal allele, with the maternal allele being transcriptionally silent. The maternally expressed H19 gene itself does not code a protein, but the RNA has growth-suppressing functions, potentially through inhibiting the translation of IGF2 RNA (47).

Specific regions of differential DNA methylation are regarded as critical for the correct allelic expression of IGF2/H19. Complete loss of methylation of the H19 promoter is reported at all stages of placental development (48). Hypomethylation of IGF2 and H19 promoters as well as the ICR of those genes has been reported in placentas derived from pregnancies complicated with fetal growth restriction (4951). Since ICR controls the expression of both H19 and IGF2 genes, which are known growth modulators, aberrant methylation in that region may be a potential link between epigenetic modifications and abnormal fetal and placental growth.

Hypomethylation of the IGF2 and H19 promoters would indicate lower transcription levels of these genes in placentas from pregnancies complicated with fetal growth restriction. Underexpression of IGF2 is a repeated event in growth-restricted placentas and it is postulated to be associated with reduced diffusional capacity of the placenta, which in turn affects fetal growth (52). However, hypomethylation of the IGF2 promoter is in contrast to the reduced transcription levels observed in placentas derived from pregnancies with abnormal fetal growth. This discrepancy suggests that there is no direct correlation between methylation and imprinted gene expression in the placenta, and other mechanisms may be involved in this sequence of molecular events. According to recent studies, methylation of the IGF2/H19 promoters is not prerequisite for the regulation of the imprinting domain that controls transcription of the two genes in human placenta (49,53). Moreover, hypomethylation of the same regions does not have an impact on the expression pattern of IGF2 and H19 (53).

Reduced methylation levels of the region that controls the imprinting of IGF2/H19 (ICR) have been reported in placentas derived from pregnancies with poor fetal growth and those complicated with preeclampsia (4951,54) (Table I). ICR is hypomethylated leading to the repression of IGF2 expression in approximately one-third of patients with Silver Russell syndrome (SRS), a syndrome associated with pre- and post-natal growth deficiency (57). However, where ICR is hypermethylated it leads to an increase in IGF2 expression in some cases of pre- and post-natal overgrowth diagnosed as Beckwith-Wiedemann syndrome (BWS) (58). Methylation at ICR has been shown in a number of studies to be particularly responsive to environmental factors such as culture media (59), environmental toxins (60,61), and prenatal ethanol exposure (61). The reduced methylation levels associated with IUGR may reflect an adaptive process serving to adjust placental and fetal growth in response to poor placental perfusion.

Table I

Methylation patterns of genes expressed in the placenta of pregnancies that delivered a growth-restricted or small for gestational age neonate.a

Table I

Methylation patterns of genes expressed in the placenta of pregnancies that delivered a growth-restricted or small for gestational age neonate.a

GeneImprintingTissueMethylationExpressionAuthor/Year (Refs.)
IGF2/H19 (ICR)YesIUGR and control placentas HypomethylationDecreased (IGF2)Bourque et al, 2010 (54)
IGF2/H19 (ICR)YesIUGR + PET and control placentasNo difference
CDKN1C (ICR)YesIUGR and control placentasNo differenceNo difference
H19YesIUGR and control placentasNo difference
CDKN1CYesIUGR and control placentasNo difference
PEG10YesIUGR and control placentasNo difference
PLAGL1YesIUGR and control placentasNo difference
SNRPNYesIUGR and control placentasNo differenceIncreased
MESTYesIUGR and control placentasNo differenceIncreased
PHLDA2YesIUGR and control placentasIncreasedMcMinn et al, 2006 (55)
MESTYesIUGR and control placentasNo differenceDecreased
SERPINA3NoIUGR and control placentas HypomethylationIncreasedChelbi et al, 2007 (56)
SERPINA3NoIUGR+ preeclampsia and control placentas HypomethylationIncreased
IGF2YesSGA placentas and neonatal blood HypomethylationGuo et al, 2008 (49)
H19YesSGA placentas and neonatal blood Hypomethylation
IGF2YesSGA and control placentas-Decreased
H19YesSGA and control placentas-No difference
H19YesIUGR and control placentas HypomethylationIncreasedKoukoura et al, 2011 (51)
IGF2/H19 (ICR)YesIUGR and control placentasNo difference
IGF2YesIUGR and control placentas HypomethylationDecreasedKoukoura et al, 2001 (50)

a Methylation levels between different samples were assessed and the findings presented (methylation and expression) refer to the values observed in the pathologic tissues in comparison to the controls.

{ label (or @symbol) needed for fn[@id='tfn2-mmr-05-04-0883'] } ICR, imprinting control center; IUGR, intrauterine growth restriction; SGA, small for gestational age; PET, preeclampsia.

Hypomethylation of the imprinted gene promoters is not a universal finding in cases where fetal growth is compromised. In their study, Lambertini et al demonstrated a slight tendency towards hypermethylation of the DMRs of all known imprinted genes identified to be expressed in growth-restricted placentas (62). These authors suggested that differential methylation changes in growth-restricted placentas occur throughout the genomic regions, encompassing genes actively expressed in the placenta. Analysis of other imprinted genes from the placentas of pregnancies complicated with IUGR, revealed a lack of altered DNA methylation at their imprinting centers (55), although they demonstrated differences in their transcription levels (Table I).

The contradictory results that stem from different studies regarding imprinted gene methylation patterns in the placenta highlight the already reported DNA methylation variation at the imprinted genes. Inter-individual, tissue-specific variation in DNA-methylation level is widespread in the human genome, with implications on phenotypic variation and disease (63). Several genes have been described to exhibit this polymorphic pattern of DNA methylation in the human placenta (64). Therefore, the exact epigenetic defects in the human placenta, which control imprinted gene expression and affect fetal development, remain to be determined.

The hypothesis that variation in the DNA methylation profile of human term placenta can serve as a marker of growth has been confirmed by Banister et al who demonstrated a pattern of methylation of 22 critical loci in human term placentas. Specific methylation alterations of these genes were highly predictive of IUGR or SGA (65). A significant association has also been shown between the differential methylation of the glucocorticoid receptor gene in the placenta and Large for Gestational Growth (LGA) infants (31). Placental gene serine protease inhibitor A3 (SERPINA3), whose expression is known to be affected by placental pathologies such as preeclampsia, has been shown to exhibit hypomethylation of its promoters in IUGR placentas. Hypomethylation coincided with increased transcription levels of the same gene in placentas derived from IUGR pregnancies as well as preeclamptic IUGR cases. The hypomethylated CpGs were found to be located at putative binding sites for developmental and stress response (hypoxia and inflammation) factors (56).

Recent studies have demonstrated significant associations between infant growth, in utero exposures and repetitive element methylation in placental tissue (66). These DNA repetitive elements are made up of interspersed and tandem repeats and comprise at least half of the human genome (67). Interspersed repeats are composed of long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs). A significant correlation was found between methylation levels and the birthweight percentile. A 10% methylation increase in LINE-1 mean levels caused the birthweight percentile to significantly increase by 9.7. Similarly, a 10% methylation increase in AluYb8 mean levels caused the birthweight percentile to significantly increase by 14.5. Furthermore, mean AluYb8 levels differed significantly due to maternal tobacco use during pregnancy; whereas, mean LINE-1 levels only significantly differed due to maternal alcohol use during pregnancy. Authors of these studies concluded that the alterations may reflect underlying functional epigenetic alterations to genes important in placental growth and development.

Previous investigations emphasized marked similarities between the proliferative, migratory and invasive properties of placental cells and those of cancer cells. Alterations in the expression of tumour suppressor gene expression profiles have been identified in placentas from preeclamptic pregnancies (68). A distinct pattern of tumour-associated methylation, linking a coordinated series of epigenetic silencing events, similar to those associated with some tumours, in the distinct, features of normal human placental invasion and function has been observed (69). A genome-wide methylation analysis revealed reduced methylation levels of trophoblastic tissues derived from chorionic villous sampling during the first trimester of pregnancy. The highly proliferative and invasive nature of early placenta may explain this relative hypomethylation as a requirement for an intensively active transcriptional state. Trophoblasts and cancer cells may use common epigenetic modifications to facilitate their proliferative, migratory and invasive properties (70). However, no data are currently available that may indicate a correlation between the epigenetic modification of tumor-associated genes and fetal growth. In a study where the methylation status of genes regulating vitamin D bioavailability and activity in the placenta was investigated, the CYP24A1 gene was methylated in human placenta, purified cytotrophoblasts, and primary and cultured chorionic villus sampling tissue, whereas vitamin D receptor (VDR) and CYP27B1 genes were non-methylated. All three genes were hypermethylated in choriocarcinoma cell lines, emphasizing the role of vitamin D deregulation in this type of cancer. The promoter methylation of the CYP24A1 gene, directly downregulated basal promoter activity and abolished vitamin D-mediated feedback activation. This event resulted in maximizing active vitamin D bioavailability at the fetomaternal interface suggesting a role in pregnancy progression (71).

Environmental impact on DNA methylation in the placenta

There is a critical window, at some stage in intrauterine life, during which balanced homeostasis is essential for normal fetal growth and development. Adverse effects during that period alter the structure and function of distinct cells, organ systems or homeostatic pathways, thereby ‘programming’ the individual for an increased risk of developing diseases in adult life. Placental phenotype is responsive to environmental conditions and may help predict the risk of adult disease programmed in utero. The placenta responds to and is potentially marked in an epigenetic context by environmental insults, suggesting that the placental epigenome serves, not only as a record of in utero exposure, but also as a mediator and/or modulator of disease pathogenesis.

Accumulating evidence suggests that the maternal nutritional status is capable of altering the epigenetic state of the fetal genome and imprinted gene expression. Ethanol-exposed midgestation placentas and embryos were severely growth retarded when compared with the controls. The relationship between placental weight and ethanol treatment suggested that this was partially dependent on DNA methylation at the CCCTC-binding factor (CTCF) site on the paternal allele in placentas (61). Preimplantation embryo culture has been shown to affect the methylation and expression of imprinted genes in several animal models. One particularly favoured explanation for the association between the environmental impact in early life and long-term physiological functions lies with the epigenetic modification of gene expression (71). Although there is strong evidence to demonstrate that the environment affects the pattern of DNA methylation during fetal development, the direct association between environmental conditions, methylation alterations and gene expression is difficult to verify (Fig. 2).

6. Conclusion

Numerous links have been made between infant growth restriction and specific epigenetic alterations, including changes to the gene imprinting status and to DNA methylation. Fetal growth is affected by the proper function of many imprinted and non-imprinted genes which are subject to epigenetic control through methylation of their promoters. DNA methylation has a critical role in placenta development, and alterations to its methylation pattern can lead to adverse placental morphology and birth outcome. However, since DNA methylation represents a delicate molecular mechanism that is easily affected by various factors, data that associate methylation patterns with placental pathology or abnormal fetal growth, should be interpreted with caution.

References

1 

M NakaoEpigenetics: interaction of DNA methylation and chromatinGene2782531200110.1016/S0378-1119(01)00721-111707319

2 

R HollidayThe inheritance of epigenetic defectsScience238163170198710.1126/science.33102303310230

3 

J Van VlietNA OatesE WhitelawEpigenetic mechanisms in the context of complex diseasesCell Mol Life Sci6415311538200717458502

4 

V BollatiA BaccarelliL HouChanges in DNA methylation patterns in subjects exposed to low-dose benzeneCancer Res67876880200710.1158/0008-5472.CAN-06-299517283117

5 

MD AnwayMK SkinnerEpigenetic programming of the germ line: effects of endocrine disruptors on the development of transgenerational diseaseReprod Biomed Online162325200810.1016/S1472-6483(10)60553-618252044

6 

JG HermanSB BaylinGene silencing in cancer in association with promoter hypermethylationN Engl J Med34920422054200310.1056/NEJMra02307514627790

7 

PW LairdThe power and the promise of DNA methylation markersNat Rev Cancer3253266200310.1038/nrc104512671664

8 

AP BirdCpG-rich islands and the function of DNA methylationNature321209213198610.1038/321209a02423876

9 

JF CostelloC PlassMethylation mattersJ Med Genet38285303200110.1136/jmg.38.5.28511333864

10 

M WeberD SchubelerGenomic patterns of DNA methylation: targets and function of an epigenetic markCurr Opin Cell Biol19273280200710.1016/j.ceb.2007.04.01117466503

11 

AP BirdAP WolffeMethylation-induced repression-belts, braces, and chromatinCell99451454199910.1016/S0092-8674(00)81532-910589672

12 

MA MaccaniCJ MarsitEpigenetics in the placentaAm J Reprod Immunol627889200910.1111/j.1600-0897.2009.00716.x

13 

LL OlignyHuman molecular embryogenesis: an overviewPediatr Dev Pathol4324343200110.1007/s10024001-0033-211441334

14 

F SantosW DeanEpigenetic reprogramming during early development in mammalsReproduction127643651200410.1530/rep.1.0022115175501

15 

W MayerA NiveleauJ WalterR FundeleT HaafDemethylation of the zygotic paternal genomeNature403501502200010.1038/3500065610676950

16 

W DeanF SantosW ReikEpigenetic reprogramming in early mammalian development and following somatic nuclear transferSemin Cell Dev Biol1493100200310.1016/S1084-9521(02)00141-612524012

17 

W DeanF SantosM StojkovicConservation of methylation reprogramming in mammalian development: aberrant reprogramming in cloned embryosProc Natl Acad Sci USA981373413738200110.1073/pnas.24152269811717434

18 

F SantosB HendrichW ReikW DeanDynamic reprogramming of DNA methylation in the early mouse embryoDev Biol241172182200210.1006/dbio.2001.050111784103

19 

KD TremblayJR SaamRS IngramSM TilghmanMS BartolomeiA paternal-specific methylation imprint marks the alleles of the mouse H19 geneNat Genet9407413199510.1038/ng0495-4077795647

20 

W ReikJ WalterGenomic imprinting: parental influence on the genomeNat Rev Genet22132200110.1038/3504755411253064

21 

AJ WoodRJ OakeyGenomic imprinting in mammals: emerging themes and established theoriesPLoS Genet2e147200610.1371/journal.pgen.002014717121465

22 

CA EdwardsAC Ferguson-SmithMechanisms regulating imprinted genes in clustersCurr Opin Cell Biol19281289200710.1016/j.ceb.2007.04.01317467259

23 

JF WilkinsD HaigWhat good is genomic imprinting: the function of parent-specific gene expressionNat Rev Genet4359368200310.1038/nrg106212728278

24 

M ConstanciaM HembergerJ HughesPlacental-specific IGF-II is a major modulator of placental and fetal growthNature417945948200210.1038/nature0081912087403

25 

D FrankW FortinoL ClarkPlacental overgrowth in mice lacking the imprinted gene IplProc Natl Acad Sci USA9974907495200210.1073/pnas.12203999912032310

26 

L LefebvreS VivilleSC BartonF IshinoEB KeverneMA SuraniAbnormal maternal behaviour and growth retardation associated with loss of the imprinted gene MestNat Genet20163169199810.1038/24649771709

27 

K TakahashiT KobayashiN Kanayamap57(Kip2) regulates the proper development of labyrinthine and spongiotrophoblastsMol Hum Reprod610191025200010.1093/molehr/6.11.101911044465

28 

RL GlaserJP RamsayIM MorisonThe imprinted gene and parent-of-origin effect database now includes parental origin of de novo mutationsNucleic Acids Res34Database issueD29D31200610.1093/nar/gkj10116381868

29 

JC RobinsCJ MarsitJF PadburySS SharmaEndocrine disruptors, environmental oxygen, epigenetics and pregnancyFront Biosci (Elite Ed)3690700201110.2741/e27921196344

30 

R SoodJL ZehnderML DruzinPO BrownGene expression patterns in human placentaProc Natl Acad Sci USA10354785483200610.1073/pnas.050803510316567644

31 

AC FilibertoMA MaccaniD KoestlerBirthweight is associated with DNA promoter methylation of the glucocorticoid receptor in human placentaEpigenetics6566572201110.4161/epi.6.5.1523621521940

32 

EC NelissenAP van MontfoortJC DumoulinJL EversEpigenetics and the placentaHum Reprod Update17397417201110.1093/humupd/dmq05220959349

33 

R ResnikIntrauterine growth restrictionObstet Gynecol99490496200210.1016/S0029-7844(01)01780-X11864679

34 

D BrodskyH ChristouCurrent concepts in intrauterine growth restrictionJ Intensive Care Med19307319200410.1177/088506660426966315523117

35 

LO LubchencoC HansmanM DresslerE BoydIntrauterine growth as estimated from liveborn birth-weight data at 24 to 42 weeks of gestationPediatrics327938001963

36 

RJ SnijdersC SherrodCM GosdenKH NicolaidesFetal growth retardation: associated malformations and chromosomal abnormalitiesAm J Obstet Gynecol168547555199310.1016/0002-9378(93)90491-Z8438926

37 

RA OdegardLJ VattenST NilsenKA SalvesenR AustgulenPreeclampsia and fetal growthObstet Gynecol96950955200010.1016/S0029-7844(00)01040-1

38 

RA WaterlandRL JirtleEarly nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseasesNutrition206368200410.1016/j.nut.2003.09.01114698016

39 

EA HousemanBC ChristensenRF YehModel-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributionsBMC Bioinformatics9365200810.1186/1471-2105-9-36518782434

40 

M ConstanciaG KelseyW ReikResourceful imprintingNature43253572004

41 

M VlahovicF Bulic-JakusG Juric-LekicA FucicS MaricD SermanChanges in the placenta and in the rat embryo caused by the demethylating agent 5-azacytidineInt J Dev Biol43843846199910707910

42 

L SermanM VlahovicM SijanThe impact of 5-azacytidine on placental weight, glycoprotein pattern and proliferating cell nuclear antigen expression in rat placentaPlacenta28803811200710.1016/j.placenta.2007.04.00117509679

43 

F RahnamaF ShafieiPD GluckmanMD MitchellPE LobieEpigenetic regulation of human trophoblastic cell migration and invasionEndocrinology14752755283200610.1210/en.2006-028816887905

44 

S KurukutiVK TiwariG TavoosidanaE PugachevaA MurrellZ ZhaoV LobanenkovW ReikR OhlssonCTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to IGF2Proc Natl Acad Sci USA1031068410689200610.1073/pnas.0600326103

45 

AL FowdenC SibleyW ReikM ConstanciaImprinted genes, placental development and fetal growthHorm Res65Suppl 35058200610.1159/00009150616612114

46 

R RandhawaP CohenThe role of the insulin-like growth factor system in prenatal growthMol Genet Metab868490200510.1016/j.ymgme.2005.07.02816165387

47 

CJ PetryKK OngBJ BarrattCommon polymorphism in H19 associated with birthweight and cord blood IGF-II levels in humansBMC Genet622200510.1186/1471-2156-6-2215885138

48 

Y JinnoY IkedaK YunEstablishment of functional imprinting of the H19 gene in human developing placentaeNat Genet1031824199510.1038/ng0795-3187670470

49 

L GuoS ChoufaniJ FerreiraAltered gene expression and methylation of the human chromosome 11 imprinted region in small for gestational age (SGA) placentaeDev Biol3207991200810.1016/j.ydbio.2008.04.02518550048

50 

O KoukouraS SifakisG SouflaLoss of imprinting and aberrant methylation of IGF2 in placentas from pregnancies complicated with fetal growth restrictionInt J Mol Med28481487201121805044

51 

O KoukouraS SifakisA ZaravinosHypomethylation along with increased H19 expression in placentas from pregnancies complicated with fetal growth restrictionPlacenta325157201110.1016/j.placenta.2010.10.01721129773

52 

CP SibleyPM CoanAC Ferguson-SmithPlacental-specific insulin-like growth factor 2 (IGF2) regulates the diffusional exchange characteristics of the mouse placentaProc Natl Acad Sci USA10182048208200410.1073/pnas.040250810115150410

53 

S TabanoP ColapietroI CetinEpigenetic modulation of the IGF2/H19 imprinted domain in human embryonic and extra-embryonic compartments and its possible role in fetal growth restrictionEpigenetics5313324201010.4161/epi.5.4.1163720418667

54 

DK BourqueL AvilaM PenaherreraP von DadelszenWP RobinsonDecreased placental methylation at the H19/IGF2 imprinting control region is associated with normotensive intrauterine growth restriction but not preeclampsiaPlacenta31197202201010.1016/j.placenta.2009.12.003

55 

J McMinnM WeiN SchupfUnbalanced placental expression of imprinted genes in human intrauterine growth restrictionPlacenta27540549200610.1016/j.placenta.2005.07.00416125225

56 

ST ChelbiF MondonH JammesExpressional and epigenetic alterations of placental serine protease inhibitors: SERPINA3 is a potential marker of preeclampsiaHypertension497683200710.1161/01.HYP.0000250831.52876.cb17088445

57 

C GicquelS RossignolS CabrolEpimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndromeNat Genet3710031007200510.1038/ng162916086014

58 

R WeksbergC ShumanAC SmithBeckwith-Wiedemann syndromeAm J Med Genet C Semin Med Genet137C1223200510.1002/ajmg.c.3005816010676

59 

AS DohertyMR MannKD TremblayMS BartolomeiRM SchultzDifferential effects of culture on imprinted H19 expression in the preimplantation mouse embryoBiol Reprod6215261535200010.1095/biolreprod62.6.152610819752

60 

Q WuS OhsakoR IshimuraJS SuzukiC TohyamaExposure of mouse preimplantation embryos to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) alters the methylation status of imprinted genes H19 and IGF2Biol Reprod7017901797200410.1095/biolreprod.103.02538714960483

61 

PC HaycockM RamsayExposure of mouse embryos to ethanol during preimplantation development: effect on DNA methylation in the H19 imprinting control regionBiol Reprod81618627200910.1095/biolreprod.108.07468219279321

62 

L LambertiniAI DiplasMJ LeeR SperlingJ ChenJ WetmurA sensitive functional assay reveals frequent loss of genomic imprinting in human placentaEpigenetics3261269200810.4161/epi.3.5.675518769151

63 

D MonkR SanchesP ArnaudImprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and humanHum Mol Genet1512591269200610.1093/hmg/ddl04116531418

64 

RK YuenL AvilaMS PenaherreraHuman placental-specific epipolymorphism and its association with adverse pregnancy outcomesPLoS One4e7389200910.1371/journal.pone.000738919838307

65 

CE BanisterDC KoestlerMA MaccaniJF PadburyEA HousemanCJ MarsitInfant growth restriction is associated with distinct patterns of DNA methylation in human placentasEpigenetics6920927201110.4161/epi.6.7.1607921758004

66 

CS Wilhelm-BenartziEA HousemanMA MaccaniIn Utero Exposures, Infant Growth, and DNA Methylation of Repetitive Element and Developmentally Related Genes in Human PlacentaEnviron Health Perspect201110.1289/ehp.110392722005006

67 

N ZamudioD Bourc’hisTransposable elements in the mammalian germline: a comfortable niche or a deadly trap?Heredity (Edinb)10592104201010.1038/hdy.2010.5320442734

68 

A HeikkiläT TuomistoSK HäkkinenL Keski-NisulaS HeinonenS Yla-HerttualaTumor suppressor and growth regulatory genes are overexpressed in severe early-onset preeclampsia-an array study on case-specific human preeclamptic placental tissueActa Obstet Gynecol Scand846796892005

69 

B NovakovicV RakyanHK NgSpecific tumour-associated methylation in normal human term placenta and first-trimester cytotrophoblastsMol Hum Reprod14547554200810.1093/molehr/gan04618708652

70 

C FerrettiL BruniV Dangles-MarieAP PeckingD BelletMolecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblastsHum Reprod Update13121141200710.1093/humupd/dml04817068222

71 

B NovakovicM SibsonHK NgPlacenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interfaceJ Biol Chem2841483814848200910.1074/jbc.M80954220019237542

72 

A RazinCpG methylation, chromatin structure and gene silencing-a three-way connectionEMBO J1749054908199810.1093/emboj/17.17.49059724627

Journal Cover

April 2012
Volume 5 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

2014 Impact Factor: 1.554
Ranked #48/123 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Koukoura, O., Sifakis, S., & Spandidos, D.A. (2012). DNA methylation in the human placenta and fetal growth (Review). Molecular Medicine Reports, 5, 883-889. http://dx.doi.org/10.3892/mmr.2012.763
MLA
Koukoura, O., Sifakis, S., Spandidos, D. A."DNA methylation in the human placenta and fetal growth (Review)". Molecular Medicine Reports 5.4 (2012): 883-889.
Chicago
Koukoura, O., Sifakis, S., Spandidos, D. A."DNA methylation in the human placenta and fetal growth (Review)". Molecular Medicine Reports 5, no. 4 (2012): 883-889. http://dx.doi.org/10.3892/mmr.2012.763